Last updated: February 14, 2026
Product Details
- Name: Osmolex ER (dexmethylphenidate extended-release)
- NDC: 65162-0676
- Indication: Attention deficit hyperactivity disorder (ADHD)
- Formulation: Extended-release tablet
Current Market Position
- Estimated annual sales: $120 million (as of 2022, IQVIA)
- Market share: Approximately 8% among ADHD medications
- Key competitors: Vyvanse (lisdexamfetamine), Adderall XR (amphetamine salts), Concerta (methylphenidate extended-release)
Regulatory Status
- FDA approval: 2017
- Patent status: US patent expected to expire in 2027; generic entry projected thereafter
- Exclusivity: Market exclusivity in effect until patent expiry
Price Analysis
Current Pricing
- Brand Price (per 30-day supply): $350–$400
- Average Wholesale Price (AWP): approximately $330 per month
- Estimated out-of-pocket (medicare, private insurance): approximately $30–$70
Pricing Trends
- Pre-patent-expiry: stable pricing, marginal increases aligned with inflation and healthcare cost trends
- Post-patent expiry: potential decline to generic prices, estimated at 50–70% of brand price, pending market adoption
| Cost Breakdown |
Component |
Cost ($) |
| Manufacturing |
50–70 per unit |
| Distribution |
10–15 per unit |
| Marketing & Sales |
15–20 per unit |
| Profit Margin |
20–30% |
Price Projections (Next 5 Years)
| Year |
Market Dynamics |
Estimated Price Range (per 30-day supply) |
Comments |
| 2023 |
Patent protection intact, stable market |
$350–$400 |
Marketing efforts maintain current prices |
| 2024 |
Patent protection, new formulations introduced |
$340–$385 |
Slight competitive pressure, possible price stabilization |
| 2025 |
Patent protection continues, minor price adjustments |
$340–$375 |
Price stabilization expected |
| 2026 |
Approaching patent expiration, increased market preparation |
$330–$370 |
Market anticipates generic launch |
| 2027+ |
Patent expires, generic entry begins |
$150–$225 |
Significant price decline with generic competition |
Factors Influencing Future Pricing
- Patent status: Patent expiry in 2027 will prompt generic competition
- Regulatory approvals: Approval of biosimilars or alternative formulations could impact prices
- Payer policies: Insurers favor lower-cost generics, driving down prices
- Market demand: Increased adherence or generic substitution will impact pricing dynamics
- Development of novel formulations: Extended-release or combination therapies may sustain higher prices
Key Takeaways
- Current prices for Osmolex ER remain stable due to exclusivity rights until 2027
- Post-patent expiry, prices are likely to decline significantly, aligning with generic market practices
- Competition from established ADHD drugs influences pricing strategies
- Future pricing depends heavily on regulatory decisions, patent landscape, and market adoption of generics
- Investment or R&D strategies should account for patent cliffs and potential entry of biosimilars or new formulations
FAQs
1. What is the expected timeline for generic entry of NDC 65162-0676?
Patent expiry is scheduled for 2027, after which generic manufacturers are likely to seek FDA approval and market entry within 1–2 years.
2. How does pricing of Osmolex ER compare with other ADHD medications?
Brand-name Osmolex ER ranges $350–$400 per month, while branded competitors like Vyvanse cost roughly $340–$375; generics of methylphenidate-based drugs retail at approximately $150–$225.
3. What regulatory factors could affect future prices?
FDA approval of biosimilars or alternative formulations, changes in patent law, or legislation promoting drug price transparency could influence prices.
4. Are there market segments more sensitive to price changes?
Medicaid, Medicare, and privately insured patients exhibit varying sensitivities; privately insured patients often experience higher out-of-pocket costs, affecting demand elasticity.
5. How might market trends impact the sustainability of current pricing?
The shift toward generic drugs post-patent expiration, the adoption of biosimilar medications, and formulary adjustments will pressure prices downward.
Citations
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2017). FDA Approval for Osmolex ER.
[3] Drugs.com. (2023). Osmolex ER Pricing and Availability.
